Pearl Therapeutics, Inc.: Series C $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Neomend, Inc.: Series D $30M

Posted in I - Series D, Q - 1Q10, R - WEST, X - Wound Healing, XX - CA

Neomend (Irvine, CA) a commercial-stage developer of sealant and adhesion-prevemtion products focused on the application to visceral pleura for open thoracotomy, closed a $30M Series D financing. Participants include Clarus Ventures, Sanderling Ventures, Novo Ventures, Vivo Ventures and Prospect Venture Partners.

Feb

2010

Zogenix, Inc.: Series B $20M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Feb

2010

Ophthotech Corp.: Series B $30M

Posted in I - Series B, Q - 4Q09, R - NORTH EAST, X - Opthalmology, XX - NJ

Ophthotech (Princeton, NJ) a clinical-stage biopharmaceutical company focused on ophthalmic therapies for wet and dry age-related macular degeneration, closed a $30M Series B financing. Participants include Clarus Ventures, SV Life Sciences, Novo Ventures and HBM BioVentures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...